Please assess the completion status of the following clinical trial:

Trial Title: Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Anti-Tumor Necrosis Factor α (Anti-TNFα) Agents (CAIN457F2309 and CAIN457F2309E1)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Male or non-pregnant, non-lactating female patients~* Presence of RA classified by ACR 2010 revised criteria for at least 3 months before screening~* At Baseline: Disease activity criteria defined by \>= 6 tender joints out of 68 and \>= 6 swollen joints out of 66~WITH at least 1 of the following at screening:~* Anti-Cyclic Citrullinated Peptide (Anti-CCP) antibodies positive OR~* Rheumatoid Factor positive~AND WITH at least 1 of the following at screening:~* High sensitivity C-Reactive Protein (hsCRP) \>= 10 mg/L OR~* Erythrocyte Sedimentation Rate (ESR) \>= 28 millimeter (mm)/1st hour~* Patients must have been taking at least one anti-TNF-α agent given at an approved dose for at least 3 months before randomization and have experienced an inadequate response to treatment or have been intolerant to at least one administration of an anti-TNF-α agent~* Patients must be taking MTX or any other DMARD (but not more than 1 DMARD) for at least 3 months before randomization and have to be on a stable dose at least 4 weeks before randomization (7.5 to 25 mg/week for MTX or other DMARD at maximum tolerated dose)~Exclusion Criteria:~* Chest x-ray with evidence of ongoing infectious or malignant process, obtained within 3 months prior to screening and evaluated by a qualified physician~* RA patients functional status class IV according to the ACR 1991 revised criteria~* Patients who have ever received biologic immunomodulating agents except for those targeting TNFα~* Previous treatment with any cell-depleting therapies~Other protocol-defined inclusion/exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- AIN457 10mg/kg - 75 mg (Type: EXPERIMENTAL): Participants received AIN457 i.v. (10 mg/kg) at Baseline (BSL), Weeks 2 and 4 then AIN457 75 mg s.c. at Week 8 and injected every 4 weeks
- AIN457 10mg/kg - 150 mg (Type: EXPERIMENTAL): Participants received AIN457 i.v. (10 mg/kg) at BSL, Weeks 2 and 4 then AIN457 150 mg s.c. at Week 8 and injected every 4 weeks
- Placebo (Type: PLACEBO_COMPARATOR): Participants received matching placebo to AIN457 until week 16 or week 24 based on responder status (\>= 20% reduction in tender and swollen joint count). Non-responders were switched to active treatment at week 16. Responders were switched to active treatment at week 24.
- Abatacept (Type: ACTIVE_COMPARATOR): Participants received abatacept (from 500 to 1000 mg i.v. based on weight). Participants who did not respond to abatacept at Week 16 were re-randomized 1:1 to AIN457 75mg or 150mg at week 24 (after an 8 week washout period).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete